Update regarding RP101 Phase II trial
As of today approximately 80 patients have been recruited in Redwood Pharma’s Phase II trial of RP101, the company’s new candidate drug against chronic dry eye in post-menopausal women. The goal is to recruit around 100 patients.CEO Martin Vidaeus stated, “We’re grateful for the significant effort our CRO, our investigators and clinics have demonstrated in the study. Redwood Pharma is well-positioned to complete recruitment and secure data crucial for the continued development of RP101 and for a future licensing deal.” About RP101RP101 is the company’s lead program for the development